JCO at ASCO 2026: Individualized Neoantigen Therapy Plus Pembrolizumab in Melanoma
JCO Editorial Fellow Dr. Ash Gurumurthi and JCO Associate Editor Dr. Grant McArthur discuss the ASCO 2026 Simultaneous Publication paper "Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study." LINK TO FULL TRANSCRIPT
▶︎
Highlights From the 2026 ASCO GU Cancers Symposium
▶︎
JCO at ASCO 2026: Neoadjuvant Sacituzumab in MIBC
▶︎
The Future of AI in Oncology: A Conversation With Google’s AI Innovators
▶︎
JCO at ASCO 2026: Pemigatinib Phase 3 FIGHT-302 Trial in Cholangiocarcinoma
▶︎
JCO at ASCO 2026: Intravesical Recombinant BCG with Chemo-Immunotherapy in MIBC
▶︎
The French Do Not Care About Work
▶︎
300 Secret Historical Photos You Were Never Supposed to See
▶︎
It's NOT Memory - 5 Early Dementia Signs Everyone Misses
▶︎
Rice with Eggs Is Better Than Pizza — I Cook It Almost Every Day!
▶︎
The Crystal That Could Destroy All Medicine
▶︎
Golden Retriever Meets Completely Broken Rescue for the First Time
▶︎
Mother's Grief: Loss Through the Lens of Motherhood
▶︎
JCO at ASCO 2026: Individual Patient Pooled Analysis of Low-Dose Tamoxifen in DCIS
▶︎
Are You Bereaved? Allowing Yourself to Grieve a Patient
▶︎
Nobody Breaks Celebrities Like Rowan Atkinson
▶︎
Day 5: Top Takeaways From ASCO26
▶︎
The Tragedy Behind the American Chopper Cast — Where Are They Now?
▶︎
ASCO26 Preview: Novel Therapies and Innovations in Cancer Care
▶︎
Stop frying eggs all the time - This is the perfect poached egg method for beginners
▶︎